Article

Decrease of nicotinic receptors in the nigrostriatal system in Parkinson's disease.

URA CNRS-CEA 2210, MIRCen, I2BM/DSV, Orsay, France.
Journal of cerebral blood flow and metabolism: official journal of the International Society of Cerebral Blood Flow and Metabolism (Impact Factor: 5.34). 06/2009; 29(9):1601-8. DOI: 10.1038/jcbfm.2009.74
Source: PubMed

ABSTRACT Smoking is associated with a lower incidence of Parkinson's disease (PD), which might be related to a neuroprotective action of nicotine. Postmortem studies have shown a decrease of cerebral nicotinic acetylcholine receptors (nAChRs) in PD. In this study, we evaluated the decrease of nAChRs in PD in vivo using positron emission tomography (PET), and we explored the relationship between nAChRs density and PD severity using both clinical scores and the measurement of striatal dopaminergic function. Thirteen nondemented patients with PD underwent two PET scans, one with 6-[(18)F]fluoro-3,4-dihydroxy-L-phenylalanine (6-[(18)F]fluoro-L-DOPA) to measure the dopaminergic function and another with 2-[(18)F]fluoro-3-[2(S)-2-azetidinylmethoxy]pyridine (2-[(18)F]fluoro-A-85380), a radiotracer with high affinity for the nAChRs. Distribution volumes (DVs) of 2-[(18)F]fluoro-A-85380 measured in the PD group were compared with those obtained from six nonsmoking healthy controls, with regions-of-interest and voxel-based approaches. Both analyses showed a significant (P <0.05) decrease of 2-[(18)F]fluoro-A-85380 DV in the striatum (-10%) and substantia nigra (-14.9%) in PD patients. Despite the wide range of PD stages, no correlation was found between DV and the clinical and PET markers of PD severity.

Download full-text

Full-text

Available from: Philippe Remy, Apr 14, 2014
0 Followers
 · 
117 Views
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: The CREB transcription factor regulates differentiation, survival, and synaptic plasticity. The complement of CREB targets responsible for these responses has not been identified, however. We developed a novel approach to identify CREB targets, termed serial analysis of chromatin occupancy (SACO), by combining chromatin immunoprecipitation (ChIP) with a modification of SAGE. Using a SACO library derived from rat PC12 cells, we identified approximately 41,000 genomic signature tags (GSTs) that mapped to unique genomic loci. CREB binding was confirmed for all loci supported by multiple GSTs. Of the 6302 loci identified by multiple GSTs, 40% were within 2 kb of the transcriptional start of an annotated gene, 49% were within 1 kb of a CpG island, and 72% were within 1 kb of a putative cAMP-response element (CRE). A large fraction of the SACO loci delineated bidirectional promoters and novel antisense transcripts. This study represents the most comprehensive definition of transcription factor binding sites in a metazoan species.
    Cell 01/2005; 119(7):1041-54. DOI:10.1016/j.cell.2004.10.032 · 33.12 Impact Factor
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: Tobacco smoking is an extremely addictive and harmful form of nicotine (NIC) consumption, but unfortunately also the most prevalent. Although disproportionately high frequencies of smoking and its health consequences among psychiatric patients are widely known, the neurobiological background of this epidemiological association is still obscure. The diverse neuroactive effects of NIC and some other major tobacco smoke constituents in the central nervous system may underlie this association. This present paper summarizes the pharmacology of NIC and its receptors (nAChR) based on a systematic review of the literature. The role of the brain's reward system(s) in NIC addiction and the results of functional and structural neuroimaging studies on smoking-related states and behaviors (i.e. dependence, craving, withdrawal) are also discussed. In addition, the epidemiological, neurobiological, and genetic aspects of smoking in several specific neuropsychiatric disorders are reviewed and the clinical relevance of smoking in these disease states addressed.
    Neuroscience & Biobehavioral Reviews 09/2009; 34(3):295-342. DOI:10.1016/j.neubiorev.2009.07.013 · 10.28 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: Parkinson's disease (PD) and atypical Parkinsonian syndromes (aPS) belong to the most common neurologic illnesses. Diagnosis and differential diagnosis of these syndromes is primarily based on well-defined clinical criteria, however, may be difficult in early and particular preclinical/premotor stages. Molecular imaging with PET offers here a broad variety of tools supporting the classification of Parkinsonian syndromes including their early and differential diagnosis, assessment of disease progression and evaluation of the efficacy of therapies. The more widely applied PET imaging techniques have focused on the assessment of neurotransmitter systems, here predominantly the pre- and postsynaptic dopaminergic functions, but also others like the serotonergic and cholinergic system. Beyond, refined methods depict distinct patterns of glucose metabolism in the various Parkinsonian syndromes, and focus on further targets such as neuroinflammation, load of amyloid plaques, and cardiac sympathetic denervation. This overview discusses the important PET applications in the field with a main emphasis on their clinical utilization but also highlights scientific applications which may grant further insights in the pathophysiology of PD and aPS.
    Neurodegenerative Diseases 01/2010; 7(5):330-40. DOI:10.1159/000314499 · 3.45 Impact Factor